Reporting to the VP Chemistry, the Principal Scientist, Chemistry will provide scientific leadership in the development and evaluation of novel targeted approaches to the treatment of liver disease. The individual will be expected to perform hands-on laboratory research, synthesize target molecules and communicate results in both written and oral forms. Persons at this level will be expected to make significant contributions in the area of medicinal chemistry and be recognized as a company-wide technical resource and an emerging thought leader in programs of interest.
Deliver on research goals and objectives.
Apply expert knowledge to proposed research projects, exploratory and formal research programs.
Coordinate interdisciplinary resources in collaboration with the research team and line management.
Propose and conduct experiments, critically evaluate data, drawing appropriate conclusions and develop a forward plan of action.
Serve as representative on a project team in area of expertise as project chemist or project leader requiring data reports and progress reports to line management.
Identify and manage external collaborating parties and/or contract research laboratories performing studies on behalf of the company.
Maintain knowledge of published developments in research field; recommend alternative approaches to research projects and programs.
Foster a spirit of cooperation, teamwork and motivation within the laboratory and department
Present scientific results in a variety of settings, both formal and informal, and both within and outside of the company.
Contribute to the development of the Arbutus patent portfolio and the scientific literature.
Mentor and manage junior staff as required; provide scientific leadership in a matrix team environment.
Additional Salary Information: bonus: options and salary available
Internal Number: 001
About Arbutus Biopharma Inc.
Arbutus Biopharma Corporation (NASDAQ: ABUS) is a publicly-traded biopharmaceutical company dedicated to discovering, developing and commercializing a cure for patients suffering from chronic hepatitis B infection, a disease of the liver caused by hepatitis B virus (HBV). We are developing a portfolio of drug candidates with complementary mechanisms of action that we believe will result in a combination therapy that will transform the HBV treatment landscape and cure hepatitis B virus disease.